SAN DIEGO, July 8, 2011 /PRNewswire/ — Stryker Joint
Preservation, a business unit of Stryker’s Orthopaedics group,
today announced at the 2011 American Orthopaedic Society for Sports
Medicine meeting that it has entered into an exclusive
collaboration with RegenLab SA to distribute Stryker’s
RegenKit-THT, a one-step system designed for the safe and rapid
preparation of autologous platelet-rich plasma (A-PRP) from a small
sample of blood at the patient’s point of care.
A-PRP contains an increased concentration of platelets, while
maintaining physiological levels of leukocytes (white blood cells).
When activated, platelets have been found to release growth
factors which may participate in the healing process, and a
multitude of proteins and bioactive factors critical to the healing
process and the recruitment of cells. Leukocytes are
responsible primarily for defending the body against infection, but
are also key players during the initial inflammation phase of
tissue healing.
In comparison to competitive offerings, the A-PRP prepared using
Stryker’s RegenKit-THT provides the highest platelet recovery and
viability(1), while its simplified single tube preparation, with a
minimal eight minute centrifuge spin time and reduced number of
steps, helps maximize efficiency in the office and O.R.
“The RegenKit-THT system is the result of 10 years of scientific
research in tissue regeneration and is designed to provide an
autologous and physiological solution to promote a biological
environment for regenerative cells enrichment. RegenLab is
pleased to collaborate with Stryker, a leader in medical
technologies and innovation, which will allow for the widespread
distribution of our A-PRP technology,” said Antoine Turzi, Founder
and CEO of RegenLab SA.
“The addition of the RegenKit for PRP therapy to Stryker’s Joint
Preservation Biologics portfolio allows us to provide surgeons with
this emerging therapy for orthopaedic applica
‘/>”/>
